| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | EMR2; EGF-like module-containing mucin-like hormone receptor-like 2; EGF-like module receptor 2; CD312 |
| Entrez GeneID | 30817; |
| WB Predicted band size | 72kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human EMR2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于EMR2抗体的3篇参考文献示例(注：文献为虚拟示例，实际文献需通过数据库验证)：
1. **文献名称**：*Targeting EMR2/ADGRE2 in cancer-associated fibroblasts with monoclonal antibody inhibits tumor progression*
**作者**：Wang, Y. et al.
**摘要**：该研究开发了一种抗EMR2单克隆抗体，通过阻断癌症相关成纤维细胞中的EMR2信号通路，抑制肿瘤微环境中的基质重塑，显著减缓了小鼠模型中实体瘤的生长和转移。
2. **文献名称**：*EMR2 as a novel therapeutic target in rheumatoid arthritis: Anti-EMR2 antibody ameliorates inflammatory responses*
**作者**：Zhang, L. et al.
**摘要**：研究发现EMR2在类风湿关节炎患者的滑膜巨噬细胞中高表达。抗EMR2抗体通过抑制炎症因子(如TNF-α和IL-6)的释放，在小鼠模型中减轻关节炎症和骨破坏。
3. **文献名称**：*Anti-EMR2 antibody-drug conjugate demonstrates efficacy in acute myeloid leukemia models*
**作者**：Chen, H. et al.
**摘要**：该研究构建了一种靶向EMR2的抗体-药物偶联物(ADC)，在急性髓系白血病细胞中显示出特异性杀伤效果，同时减少对正常造血细胞的毒性，为白血病治疗提供了新策略。
4. **文献名称**：*EMR2 regulates macrophage polarization and its blockade promotes anti-tumor immunity*
**作者**：Kim, S. et al.
**摘要**：通过抗EMR2抗体阻断EMR2功能，可诱导巨噬细胞向促炎M1表型极化，增强肿瘤微环境中的T细胞浸润，从而抑制黑色素瘤的生长并提高免疫治疗效果。
---
**提示**：实际文献可通过PubMed或Google Scholar以关键词“EMR2 antibody”或“ADGRE2 therapeutic”检索，并关注近年来的免疫治疗或肿瘤微环境相关研究。
The EMR2 antibody targets EMR2 (EGF-like module-containing mucin-like hormone receptor 2), a cell surface receptor encoded by the *ADGRE5* gene. Belonging to the adhesion G protein-coupled receptor (GPCR) family, EMR2 features a large extracellular region with epidermal growth factor (EGF)-like domains, a mucin-like stalk, and a seven-transmembrane domain. It plays a role in cell adhesion, migration, and immune regulation, primarily expressed on myeloid cells like macrophages, neutrophils, and dendritic cells.
EMR2 interacts with extracellular matrix components, such as chondroitin sulfate, through its EGF-like domains, modulating immune cell activation and inflammatory responses. Studies link EMR2 to pathological processes, including chronic inflammation, fibrosis, and cancer progression. In tumor microenvironments, EMR2 expression correlates with macrophage infiltration and tumor metastasis, making it a potential biomarker or therapeutic target.
Antibodies against EMR2 are used in research to investigate its signaling mechanisms, ligand interactions, and roles in diseases. Recent efforts focus on developing therapeutic antibodies or antagonists to block EMR2-mediated pathways in inflammatory disorders or oncology. Challenges include understanding its precise ligand-receptor dynamics and tissue-specific functions. Overall, EMR2 antibodies serve as critical tools for elucidating the receptor's biological and clinical significance.
×
